



RECEIVED
FEB 08 2002

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/516,444	02/29/2000	Patricia A. Billing-Medel	5995.US.P2

CONFIRMATION NO. 1768

23492
ABBOTT LABORATORIES
DEPT. 377 - AP6D-2
100 ABBOTT PARK ROAD
ABBOTT PARK, IL 60064-6050

FORMALITIES LETTER



OC000000006545871

Date Mailed: 09/12/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: P. A. Billing-Medel, *et al.*

Serial No.: 09/516,444

Filed: February 29, 2000

For: REAGENTS AND METHODS
USEFUL FOR DETECTING
DISEASES OF THE BREAST

Examiner: (not assigned)

Group Art Unit: 1641

Case No.: 5995.US.P2

CERTIFICATE OF MAILING (37 CFR
1.8 (a))

I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being deposited with the United States Postal
Service on the date shown below with sufficient
postage as first class mail in an envelope addressed
to the:

Assistant Commissioner for Patents
Customer Service Center
Washington, D.C. 20231, on:

Date of Deposit: November 5, 2001

Wanda C. Smith 11/5/01
Wanda E. Smith Date

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Customer Service Center
Washington, D.C. 20231

Dear Sir:

Enclosed herewith is a Statement Under 37 C.F.R. § 1.821-1.825 for P. A.
Billing-Medel, *et al.*, for REAGENTS AND METHODS USEFUL FOR DETECTING
DISEASES OF THE BREAST, the specification of which was filed on February 29,
2000, and received Serial No. 09/516,444.

Also enclosed are: Copy of Notice to Comply with Req. for Patent Appln.
Containing Nucleotide Seq. and/or Amino Acid
Seq. Disclosures ; Sequence Listing and CRF Disk.
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees
required under 37 CFR 1.16, as well as any patent application processing fees under 37
CFR 1.17 associated with this communication for which full payment has not been
tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
P. A. Billing-Medel, *et al.*

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park, Illinois 60064-6050
Phone: (847) 935-7550
FAX: (847) 938-2623

Mimi C. Goller
Mimi C. Goller
Registration No. 39,046
Attorney for Applicants

RECEIVED
FEB 08 2002
TECH CENTER 1600/2900